Viewing ovarian cancer as a "chronic disease": What exactly does this mean?

被引：26
作者：
Markman, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
GYNECOLOGIC ONCOLOGY | 2006年 / 100卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2005.08.043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：229 / 230
页数：2
相关论文
共 17 条
[1]   Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancer [J].
Dizon, DS ;
Hensley, ML ;
Poynor, EA ;
Sabbatini, P ;
Aghajanian, C ;
Hummer, A ;
Venkatraman, E ;
Spriggs, DR .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1238-1247
[2]   A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].
du Bois, A ;
Lück, HJ ;
Meier, W ;
Adams, HP ;
Möbus, V ;
Costa, S ;
Bauknecht, T ;
Richter, B ;
Warm, M ;
Schröder, W ;
Olbricht, S ;
Nitz, U ;
Jackisch, C ;
Emons, G ;
Wagner, U ;
Kuhn, W ;
Pfisterer, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330
[3]   Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer [J].
Gadducci, A ;
Bruzzone, M ;
Carnino, F ;
Ragni, N ;
Rubagotti, A ;
Conte, PF .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 (04) :286-290
[4]  
GERSHENSON DM, 1989, OBSTET GYNECOL, V73, P798
[5]   TREATMENT OF RELAPSED CARCINOMA OF THE OVARY WITH CISPLATIN OR CARBOPLATIN FOLLOWING INITIAL TREATMENT WITH THESE COMPOUNDS [J].
GORE, ME ;
FRYATT, I ;
WILTSHAW, E ;
DAWSON, T .
GYNECOLOGIC ONCOLOGY, 1990, 36 (02) :207-211
[6]   ADVANCED OVARIAN-CANCER - LONG-TERM RESULTS OF TREATMENT WITH INTENSIVE CISPLATIN-BASED CHEMOTHERAPY OF BRIEF DURATION [J].
HAINSWORTH, JD ;
GROSH, WW ;
BURNETT, LS ;
JONES, HW ;
WOLFF, SN ;
GRECO, FA .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (02) :165-170
[7]   Limits to the "benefits" from our oncologic interventions: A case report [J].
Markman, M .
GYNECOLOGIC ONCOLOGY, 2000, 78 (02) :261-262
[8]   Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design [J].
Markman, M ;
Markman, J ;
Webster, K ;
Zanotti, K ;
Kulp, B ;
Peterson, G ;
Belinson, J .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3120-3125
[9]   Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials [J].
Markman, M ;
Webster, K ;
Zanotti, K ;
Peterson, G ;
Kulp, B ;
Belinson, J .
GYNECOLOGIC ONCOLOGY, 2004, 93 (03) :699-701
[10]   Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens [J].
Markman, M ;
Kennedy, A ;
Webster, K ;
Kulp, B ;
Peterson, G ;
Belinson, J .
GYNECOLOGIC ONCOLOGY, 1997, 65 (03) :434-436
12